Who we are
Who we are
Learn more about our work and how we help accelerate the global health response.
About Unitaid
Strategy

Our organization

Work with us
What we do
What we do
Focus areas

HIV & coinfections

Tuberculosis

Malaria

Women's & children's health

Global health emergencies
Oxygen

Regional manufacturing

Climate and health

Cross-cutting priorities
Investments

Explore how our investments are shaping disease responses.
Learn more

Apply for funding

Financial grants to accelerate innovation in global health.
Learn more
Our impact

Our impact

Why Unitaid?

Learn more about the difference our work makes in the lives of people in low- and middle-income countries.
Learn more

Evaluations

External evaluations provide independent assessments of our work.

Learn more

Game-changing innovations

Explore the technologies and interventions we're working on.

Learn more
News & Events

News & events

News

All News releases Stories Opinions Videos

In the media

See where our work is being mentioned in the media world.
Learn more

Press center

Resources for journalists and media representatives.
Learn more

News Releases

Unitaid Executive Board charts future priorities at 45th session in South Africa

Unitaid invests US$22m to accelerate access to lenacapavir, a groundbreaking new HIV prevention drug

Unitaid to double its investment in maternal and newborn health with call for proposals that address preeclampsia and anemia

Learn more

Stories

The last mile in child medicine: The best HIV medicines for the youngest babies

Kenya pioneers a new tool in the fight against malaria

From principle to practice: Involving communities in research design for effective hepatitis C prevention

Learn more

Opinions

From promise to impact: Unlocking lenacapavir’s potential to end HIV

With antimicrobial resistance, women and children face highest risks

How COVID-19 unleashed a wave of medical oxygen innovation

Learn more
Publications